HomeCompareQLGN vs EPRT

QLGN vs EPRT: Dividend Comparison 2026

QLGN yields 62.31% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QLGN wins by $665.6K in total portfolio value
10 years
QLGN
QLGN
● Live price
62.31%
Share price
$3.21
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$729.0K
Annual income
$175,361.30
Full QLGN calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — QLGN vs EPRT

📍 QLGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQLGNEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QLGN + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QLGN pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QLGN
Annual income on $10K today (after 15% tax)
$5,295.95/yr
After 10yr DRIP, annual income (after tax)
$149,057.10/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, QLGN beats the other by $138,142.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QLGN + EPRT for your $10,000?

QLGN: 50%EPRT: 50%
100% EPRT50/50100% QLGN
Portfolio after 10yr
$396.2K
Annual income
$94,101.01/yr
Blended yield
23.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

QLGN
No analyst data
Altman Z
-5.6
Piotroski
3/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QLGN buys
0
EPRT buys
0
No recent congressional trades found for QLGN or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQLGNEPRT
Forward yield62.31%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$729.0K$63.4K
Annual income after 10y$175,361.30$12,840.73
Total dividends collected$608.8K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: QLGN vs EPRT ($10,000, DRIP)

YearQLGN PortfolioQLGN Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$16,931$6,230.53$11,205$505.18+$5.7KQLGN
2$27,974$9,858.52$12,672$682.46+$15.3KQLGN
3$45,156$15,223.51$14,490$930.48+$30.7KQLGN
4$71,283$22,966.14$16,786$1,282.69+$54.5KQLGN
5$110,155$33,882.50$19,753$1,791.56+$90.4KQLGN
6$166,800$48,934.07$23,677$2,541.64+$143.1KQLGN
7$247,726$69,249.85$29,008$3,672.99+$218.7KQLGN
8$361,186$96,119.21$36,463$5,425.08+$324.7KQLGN
9$517,443$130,974.20$47,238$8,221.57+$470.2KQLGN
10$729,026$175,361.30$63,385$12,840.73+$665.6KQLGN

QLGN vs EPRT: Complete Analysis 2026

QLGNStock

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Full QLGN Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this QLGN vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QLGN vs SCHDQLGN vs JEPIQLGN vs OQLGN vs KOQLGN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.